| 货号 | 11496-50mg |
| 描述 | AT-9283 is a broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50s = 3, 3, 1.2, 1.1, and 4 nM, respectively).1 It also potently (IC50=<1 μM) inhibits many other kinases, including serine/threonine kinases as well as receptor and non-receptor tyrosine kinases.1 As Aurora kinases have roles in mitosis, inhibitors of these kinases, including AT-9283, have potential in cancer therapy.2 Consistent with this, AT-9283 is effective in preventing proliferation of cancer cells both in vitroandin vivo and this effect may be enhanced by combination therapy with other chemotherapeutics.3,4 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Howard, S.,Berdini, V.,Boulstridge, J.A., et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. Journal of Medicinal Chemistry 52(2), 379-388 (2009). 2.Curry, J.,Angove, H.,Fazal, L., et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 8(12), 1921-1929 (2009). 3.Qi, W.,Liu, X.,Cooke, L.S., et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. International Journal of Cancer 130(12), 2997-3005 (2012). 4.Santo, L.,Hideshima, T.,Cirstea, D., et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clinical Cancer Research 17(10), 3259-3271 (2011). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 381.4 |
| 分子式 | C19H23N7O2 |
| CAS号 | 896466-04-9 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |